BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a strong sell rating to a sell rating in a report released on Tuesday morning.

DCPH has been the topic of a number of other reports. Zacks Investment Research upgraded shares of Deciphera Pharmaceuticals from a hold rating to a buy rating and set a $22.00 price objective on the stock in a research note on Tuesday. Leerink Swann assumed coverage on shares of Deciphera Pharmaceuticals in a research note on Monday, September 24th. They set an underperform rating and a $28.00 price objective on the stock. ValuEngine upgraded shares of Deciphera Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, October 2nd. Canaccord Genuity set a $55.00 target price on shares of Deciphera Pharmaceuticals and gave the company a buy rating in a research note on Monday, August 13th. Finally, Raymond James started coverage on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 29th. They issued an outperform rating and a $47.00 target price for the company. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating to the stock. The company presently has a consensus rating of Buy and a consensus price target of $44.00.

NASDAQ DCPH opened at $21.63 on Tuesday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 18.44 and a current ratio of 18.46. Deciphera Pharmaceuticals has a 52-week low of $15.15 and a 52-week high of $45.61. The company has a market cap of $789.38 million, a PE ratio of -7.23 and a beta of 3.79.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last released its quarterly earnings data on Thursday, November 8th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.65). On average, equities analysts predict that Deciphera Pharmaceuticals will post -2.62 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of DCPH. Bank of America Corp DE raised its holdings in shares of Deciphera Pharmaceuticals by 316.1% in the second quarter. Bank of America Corp DE now owns 2,609 shares of the company’s stock worth $103,000 after buying an additional 1,982 shares during the last quarter. Trexquant Investment LP purchased a new position in shares of Deciphera Pharmaceuticals in the second quarter worth $203,000. Rhumbline Advisers purchased a new position in shares of Deciphera Pharmaceuticals in the second quarter worth $301,000. Highland Capital Management LP purchased a new position in shares of Deciphera Pharmaceuticals in the second quarter worth $394,000. Finally, Wells Fargo & Company MN raised its holdings in shares of Deciphera Pharmaceuticals by 187.1% in the third quarter. Wells Fargo & Company MN now owns 12,440 shares of the company’s stock worth $482,000 after buying an additional 8,107 shares during the last quarter. 54.23% of the stock is owned by institutional investors and hedge funds.

Deciphera Pharmaceuticals Company Profile

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, and other solid tumors.

Further Reading: Correction

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.